TOKYO -- Japanese drugmaker Eisai hopes to begin clinical trials on a second Alzheimer's disease treatment in 2024, following up on the recent U.S. approval of lecanemab as its first.
Dementia has multiple causes. The more drugs that are made available, the higher the odds of effective treatment will be.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
